查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1402591

Alpha1 肺部疾病市场：依疾病类型、依治疗类型、依给药途径、按通路、按地区

Alpha 1 Lung Disease Market, By Disease Type (Alpha-1 Antitrypsin Deficiency, Chronic Obstructive Pulmonary Disease, Pulmonary Fibrosis, Bronchiectasis, and Others), By Treatment Type, By Route of Administration, By Distribution Channel, By Region
出版日期: | 出版商: Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3个工作天内

价格
简介目录

Alpha 1 肺部疾病市场规模预计将从 2023 年的 49.9 亿美元增至 2030 年的 167.8 亿美元，预测期内复合年增长率为 18.9%。

报告范围 报告详情
基准年 2022年 2023年市场规模 49.9亿美元
实际资料 2018-2021 预测期 2023-2030
预测期复合年增长率 18.90% 2030年市场规模预测 167.8亿美元
图 1. Alpha 1 肺部疾病市场占有率(%)（按地区），2023 年
Alpha 1 肺部疾病市场-IMG1

Alpha1 肺病是一种罕见的遗传性疾病，影响肺部和肝臟。它是由 α-1 抗胰蛋白酶 (AAT) 缺乏引起的，AAT 是一种有助于保护肺部免受损伤的蛋白质。这种疾病会导致慢性阻塞性肺病（COPD）和肝病的发展。

全球 Alpha 1 肺病市场的驱动因素包括盛行率不断上升、医疗保健专业人员意识的提高以及诊断技术的进步。根据 Alpha1 基金会估计，美国和欧洲约有 10 万人被诊断出患有 Alpha1 肺病。然而，据信受影响的实际人数要高得多。

市场动态：

α1 肺病市场主要是由盛行率上升所推动的。随着越来越多的患者被诊断出患有 α-1 肺病，对有效治疗方案的需求也不断增加。这导致市场主要企业增加了研发活动。

然而，也存在着限制市场成长的因素。一般民众和医疗保健专业人员对该疾病的认识有限，阻碍了早期诊断和治疗。此外，部分地区治疗费用高且缺乏报销政策，对市场成长构成挑战。

儘管存在这些挑战，市场仍存在一些成长机会。基因检测等诊断技术的进步预计将提高早期检测率。此外，新型疗法和标靶药物的开发为治疗 α-1 肺部疾病带来了希望。

例如，2022年6月，美国食品药物管理局（FDA）药物评估与研究中心（CDER）及其国家中心生技药品评估与研究中心（CBER）宣布：美国食品药物管理局(FDA) 药物评估与研究中心 (CDER) 和生物製药评估与研究中心(CBER) 与非营利关键路径研究所(C-Path) 合作，以降低早期死亡率和肺移植。开始规划联盟，旨在开发适用于 α-1 抗胰蛋白酶缺乏症 (AATD) 临床开发计划的工具，这是一种罕见疾病，会导致肺组织进行性破坏，从而需要我们将宣布。

本研究的主要特点

  • 本报告对全球 alpha-1 肺病市场进行了详细分析，包括预测期内（2023-2030 年）的市场规模和复合年增长率。
  • 它确定了各个细分市场的潜在收益成长机会，并为该市场说明了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
  • 研究涵盖的主要企业包括阿斯特捷利康、勃林格殷格翰国际有限公司、罗氏公司、诺华公司、辉瑞公司、默克公司、百时美施贵宝公司和武田製药有限公司。CSL Behring、Vertex Pharmaceuticals Incorporated、 Amgen Inc.、Sanofi、GSK plc、Gilead Sciences, Inc.、AbbVie Inc.、Regeneron Pharmaceuticals Inc. 等。
  • 该报告的见解使行销人员和负责人能够就未来的产品发布、产品类型升级、市场扩张和行销策略做出明智的决策。
  • 全球 Alpha 1 肺病市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 相关人员可以透过用于分析全球 Alpha 1 肺部疾病市场的各种策略矩阵来促进他们的决策。

目录

第一章 研究目的与前提

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • 连贯机会图 (COaM)

第三章市场动态、法规及趋势分析

  • 市场动态
  • 促进因素
  • 全球慢性阻塞性肺病盛行率上升
  • 提高诊断率
  • 新产品发布
  • 强大的药品管线
  • 抑制因素
  • 一般民众对此疾病的认识有限
  • 机会
  • 诊断技术的技术进步
  • 影响分析
  • 主要亮点
  • 监管场景
  • 产品发布/核准
  • PEST分析
  • 波特的分析
  • 併购场景

第 4 章 Alpha1 肺部疾病市场 –冠状病毒(COVID-19) 大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第五章 Alpha1 肺部疾病市场，依疾病类型，2023-2030 年

  • 2023年及2030年市场占有率分析（%）
  • 与前一年同期比较成长分析，2019-2030
  • 细分市场趋势
  • α1抗胰蛋白酶缺乏症
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • 慢性阻塞性肺病（COPD）
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • 肺纤维化
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • 支气管扩张
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • 其他的
  • 2018-2030年市场规模及预测、与前一年同期比较成长率

第 6 章 Alpha1 肺部疾病市场，依治疗类型，2023-2030 年

  • 2023年及2030年市场占有率分析（%）
  • 与前一年同期比较成长分析，2019-2030
  • 细分市场趋势
  • 强化治疗
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • 支气管扩张剂
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • 皮质类固醇
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • 氧气疗法
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • 肺移植
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • 其他的
  • 2018-2030年市场规模及预测、与前一年同期比较成长率

第 7 章 Alpha1 肺部疾病市场，依给药途径，2023-2030 年

  • 2023年及2030年市场占有率分析（%）
  • 与前一年同期比较成长分析，2019-2030
  • 细分市场趋势
  • 可注射的
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • 口服
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • 其他的
  • 2018-2030年市场规模及预测、与前一年同期比较成长率

第 8 章 Alpha1 肺部疾病市场，依通路，2023-2030 年

  • 2023年及2030年市场占有率分析（%）
  • 与前一年同期比较成长分析，2019-2030
  • 细分市场趋势
  • 医院药房
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • 零售药房
  • 2018-2030年市场规模及预测、与前一年同期比较成长率
  • 网路药房
  • 2018-2030年市场规模及预测、与前一年同期比较成长率

第 9 章 Alpha 1 肺部疾病市场，按地区划分，2023-2030 年

  • 2023 年和 2030 年按国家/地区分類的市场占有率分析 (%)
  • 2019-2030与前一年同期比较成长分析（按国家）
  • 各国的趋势
  • 北美洲
  • 2018-2030年市场规模及依疾病类型预测、与前一年同期比较成长率
  • 2018-2030 年市场规模与治疗类型预测、与前一年同期比较成长率
  • 2018-2030 年市场规模与按管理途径预测、与前一年同期比较成长率
  • 2018-2030年按通路分類的市场规模与预测、与前一年同期比较成长率
  • 2018-2030 年市场规模及各国预测、与前一年同期比较成长率
  • 美国
  • 加拿大
  • 欧洲
  • 2018-2030年市场规模及依疾病类型预测、与前一年同期比较成长率
  • 2018-2030 年市场规模与治疗类型预测、与前一年同期比较成长率
  • 2018-2030 年市场规模与按管理途径预测、与前一年同期比较成长率
  • 2018-2030年按通路分類的市场规模与预测、与前一年同期比较成长率
  • 2018-2030 年市场规模及各国预测、与前一年同期比较成长率
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 2018-2030年市场规模及依疾病类型预测、与前一年同期比较成长率
  • 2018-2030 年市场规模与治疗类型预测、与前一年同期比较成长率
  • 2018-2030 年与前一年同期比较管理途径分類的市场规模与预测、年成长率
  • 2018-2030年按通路分類的市场规模与预测、与前一年同期比较成长率
  • 2018-2030 年市场规模及各国预测、与前一年同期比较成长率
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
  • 拉丁美洲
  • 2018-2030年市场规模及依疾病类型预测、与前一年同期比较成长率
  • 2018-2030 年市场规模与治疗类型预测、与前一年同期比较成长率
  • 2018-2030 年与前一年同期比较管理途径分類的市场规模与预测、年成长率
  • 2018-2030年按通路分類的市场规模与预测、与前一年同期比较成长率
  • 2018-2030 年市场规模及各国预测、与前一年同期比较成长率
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 2018-2030年市场规模及依疾病类型预测、与前一年同期比较成长率
  • 2018-2030 年市场规模与治疗类型预测、与前一年同期比较成长率
  • 2018-2030 年市场规模与按管理途径预测、与前一年同期比较成长率
  • 2018-2030年按通路分類的市场规模与预测、与前一年同期比较成长率
  • 2018-2030 年市场规模及各国预测、与前一年同期比较成长率
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
  • 非洲
  • 2018-2030年市场规模及依疾病类型预测、与前一年同期比较成长率
  • 2018-2030 年市场规模与治疗类型预测、与前一年同期比较成长率
  • 2018-2030 年市场规模与按管理途径预测、与前一年同期比较成长率
  • 2018-2030年按通路分類的市场规模与预测、与前一年同期比较成长率
  • 2018-2030年按国家/地区与前一年同期比较成长率
  • 南非
  • 北非
  • 中部非洲

第10章竞争形势

  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Hoffmann-La Roche Ltd
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb
  • Takeda Pharmaceutical Company Limited.
  • CSL Behring
  • Vertex Pharmaceuticals Incorporated
  • Amgen Inc.
  • Sanofi
  • GSK plc
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Regeneron Pharmaceuticals Inc.

第11章 章节

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI6188

The Alpha 1 Lung Disease Market size is expected to reach US$ 16.78 billion by 2030, from US$ 4.99 billion in 2023, at a CAGR of 18.9% during the forecast period.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 4.99 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 18.90% 2030 Value Projection: US$ 16.78 Bn
Figure 1. Alpha 1 Lung Disease Market Share (%), by Region, 2023
Alpha 1 Lung Disease Market - IMG1

Alpha 1 Lung Disease is a rare genetic disorder that affects the lungs and liver. It is caused by a deficiency of alpha-1 antitrypsin (AAT), a protein that helps protect the lungs from damage. This condition leads to the development of chronic obstructive pulmonary disease (COPD) and liver disease.

The global Alpha 1 Lung Disease market is driven by the increasing prevalence of the disease, growing awareness among healthcare professionals, and advancements in diagnostic techniques. According to the Alpha-1 Foundation, it is estimated that around 100,000 individuals in the U.S. and Europe have been diagnosed with Alpha 1 Lung Disease. However, the actual number of affected individuals is believed to be much higher.

Market Dynamics:

The market for Alpha 1 Lung Disease is primarily driven by the rising prevalence of the disease. As more individuals are being diagnosed with Alpha 1 Lung Disease, the demand for effective treatment options is increasing. This has led to a surge in research and development activities by key players in the market.

However, there are certain factors that restrain the growth of the market. Limited awareness about the disease among the general population and healthcare professionals hinders early diagnosis and treatment. Additionally, the high cost of treatment and lack of reimbursement policies in some regions pose challenges to market growth.

Despite these challenges, the market presents several opportunities for growth. Technological advancements in diagnostic techniques, such as genetic testing, are expected to improve early detection rates. Moreover, the development of novel therapies and targeted drugs holds promise for the treatment of Alpha 1 Lung Disease.

For instance, in June 2022, U.S. Food and Drug Administration (FDA)'s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), the Center within the U.S. Food and Drug Administration (FDA) are pleased to announce their partnership with the Critical Path Institute (C-Path), a non-profit organization to initiate planning for a consortium aimed at developing tools appropriate for use in clinical development programs for alpha-1 antitrypsin deficiency (AATD), a rare disease causing progressive destruction of lung tissue leading to premature mortality or need for lung transplant.

Key Features of the Study:

  • This report provides an in-depth analysis of the global Alpha 1 Lung Disease market, including market size (US$ Bn) and Compound Annual Growth Rate (CAGR %) for the forecast period (2023-2030)
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • The key companies covered as a part of this study include AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Merck & Co., Inc., Bristol-Myers Squibb, Takeda Pharmaceutical Company Limited., CSL Behring, Vertex Pharmaceuticals Incorporated, Amgen Inc., Sanofi, GSK plc, Gilead Sciences, Inc., AbbVie Inc., and Regeneron Pharmaceuticals Inc.
  • Insights from this report would allow marketers and management authorities to make informed decisions regarding future product launches, type upgrades, market expansion, and marketing tactics
  • The global Alpha 1 Lung Disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Alpha 1 Lung Disease market

Alpha 1 Lung Disease Market Segmentation:

  • By Disease Type
    • Alpha-1 Antitrypsin Deficiency
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Pulmonary Fibrosis
    • Bronchiectasis
    • Others
  • By Treatment Type
    • Augmentation Therapy
    • Bronchodilators
    • Corticosteroids
    • Oxygen Therapy
    • Lung Transplantation
    • Others
  • By Route of Administration
    • Injectable
    • Oral
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Middle East and Africa
  • Top Companies in the Alpha 1 Lung Disease Market
    • AstraZeneca
    • Boehringer Ingelheim International GmbH
    • F.Hoffmann-La Roche Ltd
    • Novartis AG
    • Pfizer Inc.
    • Merck & Co., Inc.,
    • Bristol-Myers Squibb
    • Takeda Pharmaceutical Company Limited.
    • CSL Behring
    • Vertex Pharmaceuticals Incorporated
    • Amgen Inc.
    • Sanofi
    • GSK plc
    • Gilead Sciences, Inc.
    • AbbVie Inc.
    • Regeneron Pharmaceuticals Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Alpha 1 Lung Disease, By Disease Type
    • Market Alpha 1 Lung Disease, By Treatment Type
    • Market Alpha 1 Lung Disease, By Route of Administration
    • Market Alpha 1 Lung Disease, By Distribution Channel
    • Market Alpha 1 Lung Disease, By Region
  • Coherent Opportunity Map (COaM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Drivers
  • Rising Prevalence of COPD Globally
  • Increasing Diagnosis Rates
  • New Product Launches
  • Strong Pipeline of Drugs
  • Restraints
  • Limited awareness about the disease among the general population
  • Opportunities
  • Technological advancements in diagnostic techniques
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Alpha 1 Lung Disease Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Alpha 1 Lung Disease Market, By Disease Type, 2023-2030, (US$ Bn)

  • Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
  • Alpha-1 Antitrypsin Deficiency
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Pulmonary Fibrosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Bronchiectasis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Alpha 1 Lung Disease Market, By Treatment Type, 2023-2030, (US$ Bn)

  • Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
  • Augmentation Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
  • Bronchodilators
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
  • Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
  • Oxygen Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
  • Lung Transplantation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
  • Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)

7. Alpha 1 Lung Disease Market, By Route of Administration, 2023-2030, (US$ Bn)

  • Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
  • Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
  • Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
  • Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)

8. Alpha 1 Lung Disease Market, By Distribution Channel, 2023-2030, (US$ Bn)

  • Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
  • Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
  • Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
  • Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)

9. Alpha 1 Lung Disease Market, By Region, 2023-2030, (US$ Bn)

  • Introduction
  • Market Share Analysis, By Country, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, For Country 2019-2030
  • Country Trends
  • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • U.S.
  • Canada
  • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030,(US$ Bn)
  • South Africa
  • North Africa
  • Central Africa

10. Competitive Landscape

  • AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
  • Boehringer Ingelheim International GmbH
  • Hoffmann-La Roche Ltd
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb
  • Takeda Pharmaceutical Company Limited.
  • CSL Behring
  • Vertex Pharmaceuticals Incorporated
  • Amgen Inc.
  • Sanofi
  • GSK plc
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Regeneron Pharmaceuticals Inc.
  • Analyst Views

11. Section

  • Research Methodology
  • About us